Detalhe da pesquisa
1.
Patient-reported outcomes in relapsed ovarian cancer: results from a randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD alone.
Gynecol Oncol
; 127(1): 161-7, 2012 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-22765965
2.
Correlation between CA-125 serum level and response by RECIST in a phase III recurrent ovarian cancer study.
Gynecol Oncol
; 122(2): 350-5, 2011 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-21546066
3.
Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.
J Clin Oncol
; 34(8): 786-93, 2016 Mar 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-26371143
4.
The association between body composition and toxicities from the combination of Doxil and trabectedin in patients with advanced relapsed ovarian cancer.
Appl Physiol Nutr Metab
; 39(6): 693-8, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24869973
5.
Trabectedin as single agent in relapsed advanced ovarian cancer: results from a retrospective pooled analysis of three phase II trials.
Med Oncol
; 30(1): 435, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-23397080
6.
Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.
J Clin Oncol
; 28(19): 3107-14, 2010 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-20516432